Beyond the Cell Count: Nanovials Reveal the Secret Dialog of Disease

LOS ANGELES, CA – June 09, 2026 – For years, the frontier of biology has been the single cell. Researchers have become remarkably adept at isolating, counting, and sequencing individual cells, creating a detailed catalog of the building blocks of life. Yet, this approach has always carried a fundamental limitation: it’s like studying a society by interviewing each person in isolation. The most crucial insights—the interactions, the conflicts, the collaborations—are lost.

At the CYTO 2026 conference in West Palm Beach, Los Angeles-based Partillion Bioscience presented compelling evidence that it has developed a practical way to eavesdrop on these cellular conversations. Through a series of five scientific talks and a new preprint, the company showcased its Nanovial technology, a platform that doesn't just identify cells but captures their functional behavior as they interact. This isn't just another incremental step in cell analysis; it's a shift in perspective that could fundamentally alter how we understand disease and develop new therapies.

From Isolation to Interaction

The core of Partillion's innovation is the Nanovial itself: a microscopic hydrogel sphere with a tiny, sub-nanoliter cavity. Each one acts as an individual test tube, capable of encapsulating one or two cells. Instead of analyzing cells suspended in a chaotic mixture, researchers can now pair specific cell types—like an immune cell and a cancer cell—and observe them in a controlled microenvironment.

This elegant solution directly addresses the shortcomings of conventional methods. While powerful, traditional single-cell sequencing requires lysing (breaking open) the cell to read its genetic contents, destroying it in the process and providing only a static snapshot. Bulk analysis methods, meanwhile, average out the behavior of millions of cells, obscuring the critical actions of rare but potent cellular actors. Nanovials bridge this gap. By keeping the cells alive, the platform allows for the measurement of functional outputs over time: what molecules are they secreting? Are they activating or suppressing their neighbors? Is one cell killing another?

The new preprint, titled 'Cell-Cell-Seq Resolves Contact-Associated NK Cell Activation in Defined Tumor Cell Dyads,' provides a potent example. The research demonstrates that Nanovials can capture the very early gene expression programs that are switched on when a Natural Killer (NK) cell makes contact with a tumor cell. These subtle, contact-dependent signals are often drowned out in the noise of standard co-culture experiments, yet they represent the very first steps in the immune system's attack on cancer. Understanding this "missing layer of causality," as one researcher familiar with the field noted, is paramount for designing more effective immunotherapies.

A Pragmatic Path to Adoption

For any emerging technology, scientific novelty is only half the battle; the other half is execution and accessibility. This is where Partillion’s strategy appears particularly astute. Rather than demanding that labs invest in expensive, specialized new instrumentation, the Nanovial platform is designed to integrate with the workhorses already present in virtually every modern biology lab: flow cytometers and sequencers.

This "integration over replacement" model is a significant competitive advantage. Researchers can use standard pipetting to load cells into the Nanovials, run them through a flow cytometer to analyze and sort them based on functional readouts (like protein secretion), and then take the sorted, live cells for downstream analysis, including single-cell sequencing. By leveraging billions of dollars of existing infrastructure, the company dramatically lowers the barrier to adoption for academic labs and biotech firms alike. This pragmatic approach transforms a revolutionary technology from a niche curiosity into a scalable tool.

The industry has taken notice. The technology has been recognized with a string of accolades, including the 2020 SLAS Innovation Award and, most recently, the 2025 ISAC Technology Showcase Award. "Partillion's Nanovial technology is an exciting example of how new tools can broaden the applications of cytometry," said Jingjing Zhao, PhD, Professor at Huazhong University of Science and Technology and Chair of CYTO Innovations at ISAC. "By enabling researchers to study secreted signals, cell-cell interactions, and other functional readouts using existing workflows, this work helps bring more complex biological questions into reach."

Accelerating Therapeutic Discovery

The ultimate measure of a life science technology is its impact on human health. While still in its commercial infancy, Partillion's platform is already being positioned to accelerate therapeutic development. The ability to screen millions of individual cellular interactions provides a powerful engine for drug discovery.

Consider the challenge of finding a new antibody therapy. Traditionally, this involves a laborious process of generating and testing candidates. With Nanovials, researchers can screen millions of antibody-producing cells, isolating the rare few that secrete an antibody with the desired functional effect—for instance, one that strongly binds to a cancer cell or blocks a specific signaling pathway. This high-throughput functional screening can drastically shorten discovery timelines.

The company's multiyear partnership with Alloy Therapeutics, a firm specializing in antibody discovery, serves as a clear validation of this potential. Alloy is using Nanovials to provide advanced single-cell functional assays as a service, democratizing access to a tool that might otherwise be confined to a handful of elite labs. This practical application moves the technology from the pages of scientific journals directly into the drug development pipeline.

The Future Trajectory in a Crowded Field

Partillion Bioscience operates within the booming single-cell analysis market, a field projected to exceed $13 billion by 2030 and dominated by giants like 10x Genomics, BD, and Thermo Fisher Scientific. However, the LA-based firm, which has raised approximately $9.9 million in venture funding, has carved out a defensible niche. While many competitors focus on cataloging cell types (transcriptomics) or their spatial location (spatial biology), Partillion is focused squarely on functional interactions.

The vision, articulated by co-founder and UCLA professor Dino Di Carlo, is ambitious. He has spoken of capturing how cells "change each other over time" and has even floated the idea of a "Billion Cell × Cell Project" to map the vast network of cellular interactions.

This focus on the dynamic, functional "secret dialog" of cells is what sets the technology apart. By providing a scalable and accessible tool to listen in on these conversations, Partillion is not just contributing a new product to the market. It is empowering the entire research community to ask, and potentially answer, a new class of biological questions that lie at the heart of health and disease.